Want to see NMTC full AI Analyst Report?
NMTC Stock Chart & Stats
$1.90
-$0.15(-7.89%)
At close: 4:00 PM EDT
$1.90
-$0.15(-7.89%)
Day’s Range― - ―
52-Week Range$1.42 - $6.96
Previous CloseN/A
Volume16.98K
Average Volume (3M)532.45K
Market Cap
$17.67M
Enterprise Value$24.70
Total Cash (Recent Filing)$2.05M
Total Debt (Recent Filing)$73.32K
Price to Earnings (P/E)―
Beta1.32
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,105,763
10 Day Avg. Volume702,340
30 Day Avg. Volume532,447
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)5.04
Price to Sales (P/S)2.95
P/FCF Ratio-12.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.27Price Target Upside282.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product Revenue Growth And Gross MarginRapid OneRF adoption and positive product gross profit show commercial traction. Sustained procedure growth could expand the revenue base and provide operating leverage, although the company must maintain margins while scaling.
Low LeverageMinimal debt reduces refinancing risk, interest burden and solvency pressure while the company funds commercialization. This gives management greater flexibility to direct resources toward products and regulatory milestones.
Partnership And International Expansion InfrastructureA major commercialization partner and progress toward ISO certification can broaden distribution beyond the current U.S. base. These capabilities may support international sales and improve the scalability of NeuroOne's platform.
Bears Say
Deep Operating LossesRevenue growth has not yet translated into sustainable profitability because operating expenses substantially exceed gross profit. Continued losses could limit investment capacity and require additional financing before scale benefits emerge.
Cash Burn And Financing DependenceHeavy cash consumption and a sharply lower cash balance create ongoing funding risk despite low debt. Reliance on equity issuance could dilute shareholders and leave growth plans dependent on capital-market access.
Revenue Recognition And Execution UncertaintyA revenue-recognition error weakens reporting confidence and highlights internal-control risk during commercialization. Delays in drug delivery, international rollout and other partnered programs also reduce visibility into durable revenue conversion.
NeuroOne Medical Technologies News
NMTC FAQ
What was NeuroOne Medical Technologies’s price range in the past 12 months?
NeuroOne Medical Technologies lowest stock price was $1.42 and its highest was $6.96 in the past 12 months.
What is NeuroOne Medical Technologies’s market cap?
NeuroOne Medical Technologies’s market cap is $17.67M.
When is NeuroOne Medical Technologies’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NeuroOne Medical Technologies’s earnings last quarter?
Currently, no data Available
Is NeuroOne Medical Technologies overvalued?
According to Wall Street analysts NeuroOne Medical Technologies’s price is currently Undervalued.
Does NeuroOne Medical Technologies pay dividends?
NeuroOne Medical Technologies does not currently pay dividends.
What is NeuroOne Medical Technologies’s EPS estimate?
NeuroOne Medical Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeuroOne Medical Technologies have?
NeuroOne Medical Technologies has 9,105,763 shares outstanding.
What happened to NeuroOne Medical Technologies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeuroOne Medical Technologies?
Currently, no hedge funds are holding shares in NMTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
NMTC Earnings Call
Q2 2026
0:00 / 0:00
NMTC Stock 12 Month Forecast
Average Price Target
$7.27
▲(282.46% Upside)